IOCN UK-wide Survey: Access to Immunosuppressants for ICI Adverse Events

Have your say on a critical issue affecting immunotherapy patients across the UK.

The IOCN and UKSACT Board have written to NHS England raising concerns about inequitable access to funding for immunosuppressive medicines used to manage immune checkpoint inhibitor (ICI) toxicities.

A copy of the letter can be found here.

A meeting with NHS England is planned for late November to discuss this critical issue, and we need your input to ensure the voice of the UK immunotherapy community is heard.

Despite international guidance and real-world evidence supporting the use of biologic and JAK inhibitor therapies in managing immune-related adverse events (irAEs), access across the UK remains inconsistent—leading to significant geographical inequalities and patient risk.

Your experience is vital to shaping national policy discussions.

👉 Please complete the IOCN survey – Click the link below or scan the QR Code
🕒 It takes around 10 minutes
📅 Deadline: Monday 10th November 2026

Your feedback will help us demonstrate the scale of unmet need and highlight the real-world barriers to accessing effective immunosuppressive treatments for ICI-related toxicity.

A follow-up survey may also be circulated to gather additional insights.

Thank you for your continued support in improving equitable care for immunotherapy patients.

The Immuno-Oncology Clinical Network